Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New migraine combo drug shows promise for Tough-to-Treat patients

NCT ID NCT05550207

Symptom relief Sponsor: Axsome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called AXS-07, which combines meloxicam and rizatriptan, for treating migraine attacks in adults. The 100 participants had previously not gotten enough relief from oral CGRP inhibitors. The goal was to see if the drug could relieve headache pain and other bothersome symptoms without needing rescue medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AXS-07 (a combination of meloxicam and rizatriptan)
What this could lead to
If successful, this could provide a new acute treatment option for people with migraine who have not gotten relief from oral CGRP inhibitors.
What could go wrong
This is an open-label study with no placebo group, so results may be less reliable. The combination drug may cause side effects like dizziness or drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

100 people

The number who actually took part.

Started

Aug 2022

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has an established diagnosis of migraine with or without aura * Has experienced an inadequate response to oral CGRP inhibitors for the acute treatment of migraine Exclusion Criteria: * Pregnant, breastfeeding, or planning to become pregnant during the study * Has previously received any investigational drug or device or investigational therapy within 30 days before Screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • Clinical Research Site

    Colton, California, 92324, United States

  • Clinical Research Site

    Fullerton, California, 92835, United States

  • Clinical Research Site

    La Jolla, California, 92037, United States

  • Clinical Research Site

    Los Angeles, California, 90067, United States

  • Clinical Research Site

    Sherman Oaks, California, 91403, United States

  • Clinical Research Site

    Stamford, Connecticut, 06905, United States

  • Clinical Research Site

    DeLand, Florida, 32720, United States

  • Clinical Research Site

    Hallandale, Florida, 33009, United States

  • Clinical Research Site

    Hollywood, Florida, 33024, United States

  • Clinical Research Site

    Miami, Florida, 33126, United States

  • Clinical Research Site

    Ormond Beach, Florida, 31274, United States

  • Clinical Research Site

    Oviedo, Florida, 32765, United States

  • Clinical Research Site

    Pensacola, Florida, 32504, United States

  • Clinical Research Site

    Winter Park, Florida, 32789, United States

  • Clinical Research Site

    Stockbridge, Georgia, 30281, United States

  • Clinical Research Site

    Avon, Indiana, 46123, United States

  • Clinical Research Site

    Boston, Massachusetts, 02131, United States

  • Clinical Research Site

    North Dartmouth, Massachusetts, 02747, United States

  • Clinical Research Site

    Las Vegas, Nevada, 89102, United States

  • Clinical Research Site

    Albuquerque, New Mexico, 87102, United States

  • Clinical Research Site

    The Bronx, New York, 10466, United States

  • Clinical Research Site

    Williamsville, New York, 14221, United States

  • Clinical Research Site

    Philadelphia, Pennsylvania, 19114, United States

  • Clinical Research Site

    Charleston, South Carolina, 29406, United States

  • Clinical Research Site

    Knoxville, Tennessee, 37909, United States

  • Clinical Research Site

    Nashville, Tennessee, 37203, United States

  • Clinical Research Site

    Cypress, Texas, 77429, United States

  • Clinical Research Site

    Sugar Land, Texas, 77478, United States

  • Clinical Research Site

    Salt Lake City, Utah, 84107, United States

  • Clinical Research Site

    Charlottesville, Virginia, 22911, United States

  • Clinical Research Site

    McLean, Virginia, 22101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.